The latest price target for WAVE Life Sciences (NASDAQ:WVE) was reported by HC Wainwright & Co. on March 5, 2025. The analyst firm set a price target for $22.00 expecting WVE to rise to within 12 months (a possible 103.33% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for WAVE Life Sciences (NASDAQ:WVE) was provided by HC Wainwright & Co., and WAVE Life Sciences reiterated their buy rating.

The last upgrade for WAVE Life Sciences Ltd happened on October 16, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for WAVE Life Sciences Ltd.

There is no last downgrade for WAVE Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of WAVE Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for WAVE Life Sciences was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.

While ratings are subjective and will change, the latest WAVE Life Sciences (WVE) rating was a reiterated with a price target of $22.00 to $22.00. The current price WAVE Life Sciences (WVE) is trading at is $10.82, which is out of the analyst’s predicted range.